Find the right asset, then bring it in cleanly.
PharmaSync helps biotech and pharma buyers translate pipeline gaps into a search thesis, surface external innovation, pressure-test the asset package, and negotiate rights that fit long-term strategy – quietly, and under NDA.
A search built around your therapeutic thesis.
We define what good looks like before we go to market, so the assets you see are the ones worth your committee’s time.
Target profile
We convert pipeline gaps into a precise brief – stage, mechanism, modality, geography, economics, and the risk you are willing to carry.
Asset sourcing
We work public listings, proprietary relationships, and programs that are not yet formally marketed, measured against the thesis rather than what happens to be available.
Scientific diligence
We interrogate data quality, translational rationale, clinical comparability, IP position, regulatory route, and CMC readiness – not the summary deck.
Deal execution
We shape valuation, term design, negotiation, and internal materials through to a signed term sheet your board can stand behind.
Senior judgment where early errors get expensive.
Reach without noise
Relationships across company, academic, investor, and regional ecosystems mean we hear about assets early – and approach them discreetly.
Data fluency
Review that goes past summary slides and tests the underlying package, so risk is priced before it surprises you.
Partner-led throughout
The people who scope the mandate are the people in the room at close. Counterparty contact stays deliberate and confidential.
How an in-licensing mandate runs.
Define
Search thesis, must-have criteria, decision process, and internal alignment before any market contact.
Screen
Longlist, evidence screen, counterparty readiness, and a scored shortlist of diligence-ready candidates.
Diligence
Data-room review, specialist input, valuation range, and the structure options that fit the remaining risk.
Negotiate
Offer package, term sheet, governance points, and support through to signature.
Six lenses on every asset.
Mechanism
Biological rationale, differentiation, and the confidence that the science translates beyond the model.
Clinical evidence
Endpoint quality, population fit, safety signal, and how the comparator stacks up against standard of care.
Regulatory path
Agency precedent, data gaps, and the assumptions baked into the approval route.
CMC
Manufacturing maturity, transferability, quality systems, and supply continuity.
IP and rights
Ownership, encumbrances, scope, field restrictions, and freedom to operate.
Economics
Risk-adjusted value, milestone design, royalty load, and the real impact on your budget.
Where we source, in the regions that matter.
Asia and China-origin assets
Partner discovery, data translation, and rights review for programs moving toward Western buyers – handled with the cultural fluency the corridor requires.
Europe and UK
Academic spinouts, specialty pharma assets, and clinical networks with credible global expansion potential.
United States
Biotech, platform, and pharma-originated programs in markets where appetite and competition move fast.
The shapes a buy-side deal can take.
Exclusive license
For buyers who need defined territory or field rights.
- Upfront and milestone economics
- Royalty tiers
- Diligence obligations
Option-to-license
When one more dataset is needed before full commitment.
- Option fee and trigger package
- Exercise window
- Interim exclusivity
Co-development
When both parties keep an active development role.
- Cost share and governance
- Territory split
- Decision rights
Asset acquisition
When control matters more than ongoing sponsor participation.
- Transfer perimeter and liabilities
- Transition services
- Earnouts
Where our network runs deepest.
Oncology
ADCs, bispecifics, and targeted small molecules.
Immunology
Autoimmune and inflammation programs.
Metabolic
GLP-1 combinations, NASH, and cardiometabolic.
Cell & Gene
Autologous, allogeneic, and gene therapy.
CNS
Neurodegeneration, psychiatry, and rare neuro.
Rare Disease
Orphan and ultra-rare programs.
Devices & Dx
Devices, diagnostics, and companion Dx.
Digital Health
AI-led discovery, trial tech, and DTx.
Anonymized engagements.
ADC shortlist for regional pharma
Built a global target map and narrowed more than 40 programs to five diligence-ready candidates before a single approach.
Option structure around a data gap
Designed an option-to-license approach built around the readout the buyer needed to gain conviction.
Rights review before outreach
Surfaced field restrictions that reshaped the buyer’s preferred structure before any offer was made.